(A) Initial post-PCI antithrombotic therapy among patients with AF and a CHA₂DS₂-VASc score ≥2 and a HAS-BLED score of 1, receiving either VKA or NOAC therapy prior to PCI. (B) Longer-term antithrombotic therapy post-PCI (after the initial phase) among patients with AF and a CHA₂DS₂-VASc score ≥2 and a HAS-BLED score of 1, who received either VKA or NOAC therapy prior to PCI. (C) Initial post-PCI antithrombotic therapy among patients with AF and a CHA₂DS₂-VASc score of 4 and a HAS-BLED score of 3, receiving either VKA or NOAC therapy prior to PCI. (D) Longer-term antithrombotic therapy treatment post-PCI (after the initial phase) among patients with AF and a CHA₂DS₂-VASc score of 4 and a HAS-BLED score of 3, receiving either VKA or NOAC therapy prior to PCI. AF, atrial fibrillation; DAPT, dual antiplatelet therapy; NOAC, non-vitamin K antagonist oral anticoagulant; PCI, percutaneous coronary intervention; VKA, vitamin K antagonist.